Antisense and RNAi Therapeutics Market Expected to Witness Robust Growth, Owing to Focused R&D in Rare Diseases Like ATTR Amyloidosis and SMA
A new report from Industry Experts Inc, on " Antisense and RNAi Therapeutics ", discloses that the global market for Antisense and RNAi Therapeutics is estimated at US$5.4 billion in 2024 and is anticipated to post a CAGR of 17.8% during the 2024-2030 analysis period and stand at a projected US$14.4 billion by 2030. The antisense and RNAi therapeutics market growth is primarily driven by advancements in drug delivery technologies, like lipid nanoparticles and conjugate systems, which improve the stability and cellular uptake of RNA-based drugs. Additionally, the increasing occurrence of chronic and genetic diseases, along with the ability of these therapies to target disease-specific genes, has spurred the demand. The Antisense RNA segment is the largest market, with an estimated share of 64.1% in 2024, driven by its application in cardiovascular, respiratory, neurodegenerative, and genetic disorders. Its precision in regulating gene and protein expression enha...